how many doses of tirzepatide are in a vial Instructions BPI Labs - DiversifyRx

10.1111/liv.14274 243

In a separate phase three trial called "SOUL," Novo Nordisk's oral semaglutide lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four years on average in patients with diabetes and established heart disease, with or without chronic kidney disease

For individuals taking GLP-1 medications (e.g., Ozempic, Wegovy, or Mounjaro), making thoughtful choices about meals and snacks can help support overall dietary goals

Patients should pursue this approach only under documented informed consent, baseline metabolic and inflammatory assessment, and structured monitoring protocols

The therapy was shown to be safe, well tolerated and possibly beneficial for symptoms